PMA device
Augment® Bone Graft
Biomimetic Therapeutics, LLC · Filler, Bone Void, Synthetic Peptide (NOX, Class III) · First FDA decision Sep 1, 2015, newest Jun 13, 2022
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
8
PMA pathway
Device trials
1,782
Naming "Augment"
MAUDE reports
0
Brand "Augment", since 2015
PubMed studies
48,500
Mentioning "Augment"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Augment® Bone Graft
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 0 of 8 decisions filed under this name.
FDA's records could not be loaded.
Older decisions: P100006-S002, P100006
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Augmentative and Alternative Communication (AAC) Devices for Speech ImpairmentNational analysisReview closedCAG-00055NUpdated Sep 14, 2026
- Percutaneous Vertebral Augmentation (PVA) for Vertebral Compression Fracture (VCF)Local determinationIn effectL38213WPS Insurance CorporationUpdated Jul 24, 2026
- Percutaneous Vertebral Augmentation (PVA) for Osteoporotic Vertebral Compression Fracture (VCF)Local determinationIn effectL33569Wellpoint FederalUpdated Jul 14, 2026
- Lower Esophageal Magnetic Sphincter AugmentationLocal determinationIn effectL39780Palmetto GBAUpdated Dec 8, 2025
- Percutaneous Vertebral Augmentation (PVA) for Vertebral Compression Fracture (VCF)Local determinationIn effectL38201CGS Administrators, LLCUpdated Nov 14, 2025
- Percutaneous Vertebral Augmentation (PVA) for Vertebral Compression Fracture (VCF)Local determinationIn effectL38737Palmetto GBAUpdated Nov 14, 2025
- Percutaneous Vertebral Augmentation (PVA) for Osteoporotic Vertebral Compression Fracture (VCF)Local determinationIn effectL34228Noridian Healthcare Solutions, LLCUpdated Nov 13, 2025
- Percutaneous Vertebral Augmentation (PVA) for Vertebral Compression Fracture (VCF)Local determinationIn effectL35130Novitas Solutions, Inc.Updated May 21, 2021
Clinical trials
Device studies on ClinicalTrials.gov that name "Augment", any status and sponsor, newest update first.
Seoul National University HospitalAcademic, hospital or other
NCT05776706 · 80 participants (planned) · Start Sep 8, 2026 · Primary completion Dec 31, 2026
Device: AR-based navigation · For: Brain Neoplasms; Cerebral Aneurysm; Cerebral Arteriovenous Malformation and 1 more
Sites: Seoul, South Korea · 2 sites in all
Universitas IndonesiaAcademic, hospital or other
NCT06436222 · 60 participants · Start May 20, 2024 · Primary completion Dec 31, 2024
Device: HVNI · For: Respiratory Distress, Newborn
Sites: Jakarta Pusat, Indonesia
Infinite Biomedical TechnologiesNot on our public-company list
NCT05975970 · 5 participants · Start Oct 2, 2023 · Primary completion Jan 27, 2026
Device: MyoTrain AR · For: Amputation; Upper Limb
Sites: Edmonton, Canada
1,779 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Augment", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code NOX
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Augment"[tiab]. The summary above synthesizes these.
- Motor Learning Following Stroke: Mechanisms of Learning and Techniques to Augment Neuroplasticity.
Winterbottom L, Nilsen DM · Phys Med Rehabil Clin N Am · 2024Review
- Treg cells augment self-tolerance during infection.
Kawakami R, Sakaguchi S · Nat Immunol · 2025
- Nutritional interventions to augment immunity for COVID-19.
Singh S, Singh RK · Nutr Diabetes · 2022Letter, Research Support, Non-U.S. Gov't
- Keeping cells fit.
Rambout X, Maquat LE · Science · 2026
- Resilience in the Nurse Scientist.
Nichols LS · J Obstet Gynecol Neonatal Nurs · 2024Editorial
- Bacterial strains augment cancer therapeutics.
Hall LJ, Robinson SD · Nat Microbiol · 2021Comment
- Ultrasound Imaging/Guidance to Augment Musculoskeletal Interventions.
Güvener O, Ricci V, Özçakar L · Korean J Radiol · 2022Letter, Comment
- AR blockers augment melanoma treatment.
Willson J · Nat Rev Cancer · 2022Comment
- Ketogenic diet in cancer management.
Talib WH, Al-Dalaeen A, Mahmod AI · Curr Opin Clin Nutr Metab Care · 2023Review, Research Support, Non-U.S. Gov't
- Augment Reality-Based Teaching Practice.
Wu Y, Zhang M, Li X, et al. · Biomed Eng Educ · 2021
- Maternal antibiotics augment hyperoxia-induced lung injury in neonatal mice.
Lal CV, Ambalavanan N · Am J Physiol Lung Cell Mol Physiol · 2020Editorial, Research Support, N.I.H., Extramural
- Microbiology: Gut microbes augment neurodegeneration.
Erny D, Prinz M · Nature · 2017News, Comment
Other devices of this type
Also filed under product code NOX.
- i-FACTOR® Peptide Enhanced Bone GraftCerapedics, LLC · PMA 2024
- AUGMENT InjectableBiomimetic Therapeutics, LLC · PMA 2019
- PearlMatrix P-15 Peptide Enhanced Bone Graft (PearlMatrix Bone Graft)Cerapedics, Inc. · PMA 2025
- PearlMatrix Bone GraftCerapedics, Inc. · PMA 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.